{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-128653","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.712870+00:00","generated_at":"2026-06-21T01:28:46.955556+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Path stockholders approve 2022 Stock Incentive Plan, elect five directors","bullets":["Approved 2022 Stock Incentive Plan authorizing up to 1,300,000 shares for equity awards.","Re-elected directors: Peter H. Nielsen, Heath W. Cleaver, Paul D. Aubert, Aline Sherwood, Douglas P. Morris.","Advisory vote on executive compensation approved (2,076,879 for, 237,410 against).","Ratified Ernst & Young as independent auditor for fiscal 2022 (3,920,967 for, 300,923 against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-128653","json":"https://secwatch.observer/filing/0001104659-22-128653.json","markdown":"https://secwatch.observer/filing/0001104659-22-128653.md","text":"https://secwatch.observer/filing/0001104659-22-128653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/0001104659-22-128653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T01:28:46.955556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34310e2d92d8a48da6fb101617343c2571f1a1ef","claim":"BIO-PATH HOLDINGS, INC. shareholders approved Non-binding advisory approval of the compensation of the Company’s named executive officers.","evidence_excerpt":"Proposal 3 : For the non-binding advisory approval of the compensation of the Company’s named executive officers: Shares Voted “For” Shares Voted “Against” Shares Abstained Broker Non- Votes 2,076,879 237,410 25,588 1,937,120","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/0001104659-22-128653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"9bf6ac70c26b4ba2d7ebe7407d9172afd51e2681","claim":"BIO-PATH HOLDINGS, INC. shareholders approved Election of Directors.","evidence_excerpt":"Proposal 1 : For the election of directors of the Company, to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified: Name of Nominee Shares Voted “For” Shares Voted “Against” Shares Withheld Shares Abstained Broker Non- Votes Peter H. Nielsen 2,154,714 -- 185,163 -- 1,937,120 Heath W. Cleaver 2,094,257 -- 245,620 -- 1,937,120 Paul D. Aubert 2,127,552 -- 212,325 -- 1,937,120 Aline Sherwood 2,173,586 -- 166,291 -- 1,937,120 Douglas P. Morris 2,166,978 -- 172,899 -- 1,937,120","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/0001104659-22-128653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"d5dc569c2670dd1c8db292b3e3ff7d0c7c317347","claim":"BIO-PATH HOLDINGS, INC. shareholders approved Approval of the 2022 Plan.","evidence_excerpt":"Proposal 2 : For the approval of the 2022 Plan: Shares Voted “For” Shares Voted “Against” Shares Abstained Broker Non- Votes 1,996,284 280,998 62,595 1,937,120","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/0001104659-22-128653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"e404a2583a20c21384dcae9683af1ff6acecc117","claim":"BIO-PATH HOLDINGS, INC. shareholders approved Ratification and approval of the appointment of Ernst & Young, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2022 at the 2022-12-31 meeting.","evidence_excerpt":"Proposal 4 : For the ratification and approval of the appointment of Ernst & Young, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2022: Shares Voted “For” Shares Voted “Against” Shares Abstained Broker Non- Votes 3,920,967 300,923 55,107 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/0001104659-22-128653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}